View ValuationQuest Laboratories 将来の成長Future 基準チェック /06現在、 Quest Laboratoriesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 24% over the past year.分析記事 • Jun 02Here's Why We Think Quest Laboratories (NSE:QUESTLAB) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...お知らせ • May 27Quest Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Quest Laboratories Limited announced that they will report Q4, 2026 results on May 29, 2026New Risk • May 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Market cap is less than US$100m (₹2.13b market cap, or US$22.5m).Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹152, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past year.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹127, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.5% over the past year.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹110, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 12% over the past year.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.46 (vs ₹1.70 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.46 (up from ₹1.70 in 3Q 2025). Revenue: ₹311.8m (up 1.7% from 3Q 2025). Net income: ₹40.3m (up 45% from 3Q 2025). Profit margin: 13% (up from 9.1% in 3Q 2025). The increase in margin was primarily driven by lower expenses.分析記事 • Feb 12Does Quest Laboratories (NSE:QUESTLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). High level of non-cash earnings (33% accrual ratio). Minor Risk Market cap is less than US$100m (₹2.12b market cap, or US$23.4m).Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹129, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 17% over the past year.お知らせ • Feb 06Quest Laboratories Limited to Report Q3, 2026 Results on Feb 13, 2026Quest Laboratories Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (33% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹1.60b market cap, or US$17.8m).Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹109, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.1% over the past year.分析記事 • Nov 21Concerns Surrounding Quest Laboratories' (NSE:QUESTLAB) PerformanceQuest Laboratories Limited's ( NSE:QUESTLAB ) healthy profit numbers didn't contain any surprises for investors. We...お知らせ • Nov 13Quest Laboratories Limited to Report First Half, 2026 Results on Nov 13, 2025Quest Laboratories Limited announced that they will report first half, 2026 results on Nov 13, 2025お知らせ • Sep 04Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025, at 12:30 Indian Standard Time.Reported Earnings • Jul 26First quarter 2026 earnings released: EPS: ₹2.50 (vs ₹0.90 in 1Q 2025)First quarter 2026 results: EPS: ₹2.50 (up from ₹0.90 in 1Q 2025). Revenue: ₹231.8m (up 52% from 1Q 2025). Net income: ₹41.0m (up 178% from 1Q 2025). Profit margin: 18% (up from 9.7% in 1Q 2025). The increase in margin was driven by higher revenue.分析記事 • Jul 26A Piece Of The Puzzle Missing From Quest Laboratories Limited's (NSE:QUESTLAB) 28% Share Price ClimbQuest Laboratories Limited ( NSE:QUESTLAB ) shares have had a really impressive month, gaining 28% after a shaky period...Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹108, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 25% over the past year.New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹1.54b market cap, or US$18.0m).New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.43b market cap, or US$16.8m).New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (₹1.71b market cap, or US$20.0m).Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹83.75, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year.Board Change • May 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹115, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 29x in the Pharmaceuticals industry in India.Board Change • Mar 06Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹150, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.Recent Insider Transactions • Jan 21Chairman & MD recently bought ₹1.2m worth of stockOn the 15th of January, Anil Sabarwal bought around 10k shares on-market at roughly ₹130 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹4.2m. Anil has been a buyer over the last 12 months, purchasing a net total of ₹6.7m worth in shares.Recent Insider Transactions • Jan 07Chairman & MD recently bought ₹4.2m worth of stockOn the 2nd of January, Anil Sabarwal bought around 34k shares on-market at roughly ₹125 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anil's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹128, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India.分析記事 • Nov 22Quest Laboratories' (NSE:QUESTLAB) Solid Profits Have Weak FundamentalsQuest Laboratories Limited's ( NSE:QUESTLAB ) stock was strong after they recently reported robust earnings. However...Reported Earnings • Nov 16First half 2025 earnings released: EPS: ₹4.89 (vs ₹4.42 in 1H 2024)First half 2025 results: EPS: ₹4.89 (up from ₹4.42 in 1H 2024). Revenue: ₹434.6m (up 6.0% from 1H 2024). Net income: ₹80.1m (up 46% from 1H 2024). Profit margin: 18% (up from 13% in 1H 2024).Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹91.50, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 38x in the Pharmaceuticals industry in India.分析記事 • Oct 22Not Many Are Piling Into Quest Laboratories Limited (NSE:QUESTLAB) Just YetQuest Laboratories Limited's ( NSE:QUESTLAB ) price-to-earnings (or "P/E") ratio of 15.7x might make it look like a...Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Sep 06Quest Laboratories Limited Appoints Executive DirectorsQuest Laboratories Limited at the AGM held on September 4, 2024 approved the regularisation of additional director Mr. Vinayak Sabarwal and Mr. Umendra Singh by appointing them as Executive Directors of the Company.お知らせ • Aug 12Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024, at 16:30 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹128, the stock trades at a trailing P/E ratio of 41.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Quest Laboratories は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:QUESTLAB - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20251,259214N/AN/AN/A9/30/20251,101142-207-141N/A6/30/20251,118162N/AN/AN/A3/31/20251,040136-268-233N/A12/31/202477967N/AN/AN/A9/30/2024842118-53-31N/A6/30/202477384N/AN/AN/A3/31/20248261012130N/A3/31/202361650939N/A3/31/2022595411535N/A3/31/20213047517N/A3/31/20202643512N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: QUESTLABの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: QUESTLABの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: QUESTLABの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: QUESTLABの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: QUESTLABの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: QUESTLABの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 22:34終値2026/06/11 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Quest Laboratories Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 24% over the past year.
分析記事 • Jun 02Here's Why We Think Quest Laboratories (NSE:QUESTLAB) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
お知らせ • May 27Quest Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Quest Laboratories Limited announced that they will report Q4, 2026 results on May 29, 2026
New Risk • May 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Market cap is less than US$100m (₹2.13b market cap, or US$22.5m).
Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹152, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past year.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹127, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.5% over the past year.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹110, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 12% over the past year.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.46 (vs ₹1.70 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.46 (up from ₹1.70 in 3Q 2025). Revenue: ₹311.8m (up 1.7% from 3Q 2025). Net income: ₹40.3m (up 45% from 3Q 2025). Profit margin: 13% (up from 9.1% in 3Q 2025). The increase in margin was primarily driven by lower expenses.
分析記事 • Feb 12Does Quest Laboratories (NSE:QUESTLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). High level of non-cash earnings (33% accrual ratio). Minor Risk Market cap is less than US$100m (₹2.12b market cap, or US$23.4m).
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹129, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 17% over the past year.
お知らせ • Feb 06Quest Laboratories Limited to Report Q3, 2026 Results on Feb 13, 2026Quest Laboratories Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (33% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹1.60b market cap, or US$17.8m).
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹109, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.1% over the past year.
分析記事 • Nov 21Concerns Surrounding Quest Laboratories' (NSE:QUESTLAB) PerformanceQuest Laboratories Limited's ( NSE:QUESTLAB ) healthy profit numbers didn't contain any surprises for investors. We...
お知らせ • Nov 13Quest Laboratories Limited to Report First Half, 2026 Results on Nov 13, 2025Quest Laboratories Limited announced that they will report first half, 2026 results on Nov 13, 2025
お知らせ • Sep 04Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025, at 12:30 Indian Standard Time.
Reported Earnings • Jul 26First quarter 2026 earnings released: EPS: ₹2.50 (vs ₹0.90 in 1Q 2025)First quarter 2026 results: EPS: ₹2.50 (up from ₹0.90 in 1Q 2025). Revenue: ₹231.8m (up 52% from 1Q 2025). Net income: ₹41.0m (up 178% from 1Q 2025). Profit margin: 18% (up from 9.7% in 1Q 2025). The increase in margin was driven by higher revenue.
分析記事 • Jul 26A Piece Of The Puzzle Missing From Quest Laboratories Limited's (NSE:QUESTLAB) 28% Share Price ClimbQuest Laboratories Limited ( NSE:QUESTLAB ) shares have had a really impressive month, gaining 28% after a shaky period...
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹108, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 25% over the past year.
New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹1.54b market cap, or US$18.0m).
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.43b market cap, or US$16.8m).
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (₹1.71b market cap, or US$20.0m).
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹83.75, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year.
Board Change • May 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹115, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 29x in the Pharmaceuticals industry in India.
Board Change • Mar 06Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹150, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.
Recent Insider Transactions • Jan 21Chairman & MD recently bought ₹1.2m worth of stockOn the 15th of January, Anil Sabarwal bought around 10k shares on-market at roughly ₹130 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹4.2m. Anil has been a buyer over the last 12 months, purchasing a net total of ₹6.7m worth in shares.
Recent Insider Transactions • Jan 07Chairman & MD recently bought ₹4.2m worth of stockOn the 2nd of January, Anil Sabarwal bought around 34k shares on-market at roughly ₹125 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anil's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹128, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India.
分析記事 • Nov 22Quest Laboratories' (NSE:QUESTLAB) Solid Profits Have Weak FundamentalsQuest Laboratories Limited's ( NSE:QUESTLAB ) stock was strong after they recently reported robust earnings. However...
Reported Earnings • Nov 16First half 2025 earnings released: EPS: ₹4.89 (vs ₹4.42 in 1H 2024)First half 2025 results: EPS: ₹4.89 (up from ₹4.42 in 1H 2024). Revenue: ₹434.6m (up 6.0% from 1H 2024). Net income: ₹80.1m (up 46% from 1H 2024). Profit margin: 18% (up from 13% in 1H 2024).
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹91.50, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 38x in the Pharmaceuticals industry in India.
分析記事 • Oct 22Not Many Are Piling Into Quest Laboratories Limited (NSE:QUESTLAB) Just YetQuest Laboratories Limited's ( NSE:QUESTLAB ) price-to-earnings (or "P/E") ratio of 15.7x might make it look like a...
Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 06Quest Laboratories Limited Appoints Executive DirectorsQuest Laboratories Limited at the AGM held on September 4, 2024 approved the regularisation of additional director Mr. Vinayak Sabarwal and Mr. Umendra Singh by appointing them as Executive Directors of the Company.
お知らせ • Aug 12Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024, at 16:30 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹128, the stock trades at a trailing P/E ratio of 41.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.